Total submissions: 5
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Gene |
RCV001718857 | SCV000513979 | likely benign | not provided | 2019-10-17 | criteria provided, single submitter | clinical testing | |
Labcorp Genetics |
RCV000472283 | SCV000562378 | likely benign | Pitt-Hopkins-like syndrome 2 | 2024-01-27 | criteria provided, single submitter | clinical testing | |
Ambry Genetics | RCV002374630 | SCV002692003 | likely benign | Inborn genetic diseases | 2019-10-23 | criteria provided, single submitter | clinical testing | This alteration is classified as likely benign based on a combination of the following: seen in unaffected individuals, population frequency, intact protein function, lack of segregation with disease, co-occurrence, RNA analysis, in silico models, amino acid conservation, lack of disease association in case-control studies, and/or the mechanism of disease or impacted region is inconsistent with a known cause of pathogenicity. |
Fulgent Genetics, |
RCV002502478 | SCV002808957 | likely benign | Pitt-Hopkins-like syndrome 2; Chromosome 2p16.3 deletion syndrome | 2022-05-10 | criteria provided, single submitter | clinical testing | |
Prevention |
RCV004539775 | SCV004765164 | likely benign | NRXN1-related disorder | 2023-06-22 | no assertion criteria provided | clinical testing | This variant is classified as likely benign based on ACMG/AMP sequence variant interpretation guidelines (Richards et al. 2015 PMID: 25741868, with internal and published modifications). |